2026-04-13T06:51:14Zhttps://recercat.cat/oai/requestoai:recercat.cat:2445/1266152025-12-05T12:18:45Zcom_2072_1057col_2072_478916col_2072_478917
RECERCAT
author
Castellote Alonso, José
author
Girbau, Anna
author
Arajol, Claudia
author
Xiol Quingles, Xavier
2018-11-30T10:16:04Z2018-11-30T10:16:04Z2011-102018-07-24T12:59:18Z
Letters to the EditorDear Editor, Thrombocytopenia is a common complication seen in patients
with chronic liver disease, precluding or interfering invasive diagnostic
and therapeutic procedures. Etiology is multifactorial,
including hypersplenism, bone marrow suppression by HCV and
a possible reduction in the level or activity of the hematopoietic
growth factor thrombopoietin (TPO)(1). In addition to thrombocytopenia,
functional platelet defects has been suggested. Romiplostim
(Nplate®, Amgen Inc, Thousands Oaks, Calif) is a new
thrombopoietin receptor agonist indicated for the treatment of
thrombocytopenia in patients with chronic immune thrombocytopenic
purpura who have had an insufficient response to corticosteroids,
immunoglobulin or splenectomy (2). It has been not
tested in chronic liver disease until now. Another thrombopoietin
receptor agonist, eltrombopag (3), has been tested in chronic liver
disease undergoing an elective invasive procedure. Although
results were satisfactory in terms of platetelet count and avoidance
of platelet transfusions, the trial was early stopped due to the
observed incidence of portal vein thrombosis in the study group
(4). We report a case of a Jehovah’s Witness that could successfully
managed with romiplostim use...
(c) Aran Ediciones, 2011 info:eu-repo/semantics/openAccess
Malalties del fetge
Malalties cròniques
Liver diseases
Chronic diseases
Romiplostim in chronic liver disease with severe thrombocytopenia undergoing an elective invasive procedure
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion